01346nas a2200205   4500000000100000008004100001260001600042653002100058653001200079100001500091700001400106700001700120700001600137700001400153245007400167856015300241300001100394520072100405022001401126       2022                            d  bElsevier BV10aGeneral Medicine10aSurgery1 aUwishema O1 aSapkota S1 aWellington J1 aOnyeaka CVP1 aOnyeaka H00aLeishmaniasis control in the light of the COVID-19 pandemic in Africa  uhttps://www.sciencedirect.com/science/article/pii/S2049080122010238/pdfft?md5=5e1709834eb660d3fccbd2603514a82b&pid=1-s2.0-S2049080122010238-main.pdf  a1042633 a<p>Leishmaniasis is a parasitic disease, endemic to Africa, Asia, and South America due to inadequate access to medication and underreporting of leishmaniasis cases. Leishmaniasis has two forms: cutaneous and visceral. The fight against leishmaniasis has been greatly affected by the coronavirus disease 2019 (COVID-19) pandemic that impacted resource distribution and access to medication. Continuous effort in vaccine development and affordable therapeutics are necessary to eliminate leishmaniasis in low-income countries. Further research is necessary to determine molecular drug resistance markers in leishmaniasis patients. In this analysis, we focus on the effect of COVID-19 on leishmaniasis in Africa.</p>
  a2049-0801